Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Li...(of the two availablepeginterferon regime...),Health

Mark Sulkowski, M.D., and John McHutchison, M.D., are the co-principal investigators of the IDEAL study. They also are co-chairmen of the IDEAL Publication Committee, which also includes three independent expert members not associated with the study to provide an unbiased evaluation of the data. The Publication Committee was responsible for the preparation of the prespecified data analysis plan for the statistical analysis conducted for the primary publication of the study results.

About PEGINTRON

In the United States, PEGINTRON is indicated for use alone or with ribavirin for the treatment of chronic hepatitis C in patients with compensated liver disease who have not been previously treated with interferon alpha and who are at least 18 years of age.

Important Safety Information Regarding U.S. Labeling for PEGINTRON and REBETOL

Alpha interferons, including PEGINTRON and INTRON(R) A, may cause or aggravate fatal or life-threatening neuropsychiatric, autoimmune, ischemic, and infectious disorders. Patients should be monitored closely with periodic clinical and laboratory evaluations. Patients with persistently severe or worsening signs or symptoms of these conditions should be withdrawn from therapy. In many, but not all cases, these disorders resolve after stopping PEGINTRON and/or INTRON A therapy.

Use with Ribavirin: Ribavirin may cause birth defects and/or death of the unborn child. Extreme care must be taken to avoid pregnancy in female patients and in female partners of male patients. Ribavirin causes hemolytic anemia. The anemia associated with REBETOL therapy may result in a worsening of cardiac disease. Ribavirin is genotoxic and mutagenic and should be considered a potential
'/>"/>